Memantine

also known as memantine hydrochloride · Namenda · EBIXA · FP01 · Memantine HCl · MEM · Akatinol memantine · Axura · +15 more

Developed for: Alzheimer disease · cognitive disorder · autism · dementia · depressive disorder · major depressive disorder · Parkinson disease · amyotrophic lateral sclerosis
+74 more
· Down syndrome · neuropathy, painful · schizophrenia · autism spectrum disorder · bipolar disorder · cognitive impairment with or without cerebellar ataxia · multiple sclerosis · alcohol dependence · alcohol-related disorders · amnestic disorder · bipolar II disorder · cardiac rhythm disease · central nervous system cancer · chemotherapy-induced neuropathy · fragile X syndrome · frontotemporal dementia · glioblastoma · hepatocellular carcinoma · intellectual disability · kleptomania · Lewy body dementia · metastatic malignant neoplasm in the brain · neurotic excoriation · obsessive-compulsive disorder · open-angle glaucoma · pathologic nystagmus · sickle cell disease · traumatic brain injury · trichotillomania · AIDS dementia complex · amphetamine abuse · aphasia · attention deficit-hyperactivity disorder · autism spectrum disorder 1 · binge eating disorder · body dysmorphic disorder · bulimia nervosa · castration-resistant prostate carcinoma · cocaine dependence · complex regional pain syndrome type 1 · delirium · epilepsy · essential tremor · fragile X-associated tremor/ataxia syndrome · generalized anxiety disorder · gliosarcoma · heroin dependence · Huntington disease · nicotine dependence · opiate dependence · pathological gambling · poisoning · post-traumatic stress disorder · prostate neuroendocrine neoplasm · radiation-induced disorder · schizoaffective disorder · semantic dementia · small cell lung carcinoma · social phobia · subjective cognitive decline · substance abuse · substance-related disorder · systemic lupus erythematosus · bipolar depression · bipolar I disorder · borderline personality disorder · childhood-onset epilepsy syndrome with developmental and/or epileptic encephalopathy · fibromyalgia · ischemic stroke · migraine disorder · movement disorder · non-verbal learning disability · peripheral neuropathy · psychotic disorder
Investigated by: Forest Laboratories · H. Lundbeck A/S · Merz Pharmaceuticals GmbH · National Cheng-Kung University Hospital · Mclean Hospital · National Institute on Drug Abuse (NIDA)
+145 more
· New York State Psychiatric Institute · Massachusetts General Hospital · Stanford University · Yale University · Avalo Therapeutics, Inc. · Ministry of Science and Technology, Taiwan · NRG Oncology · National Cancer Institute (NCI) · National Institute of Mental Health (NIMH) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · University Hospital, Clermont-Ferrand · University of Chicago · University of Rochester · University of Texas Southwestern Medical Center · Allergan · Chong Kun Dang Pharmaceutical · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Hospices Civils de Lyon · Indiana University · Inova Health Care Services · Lyndra Inc. · National Institute on Aging (NIA) · Novartis · UNC Lineberger Comprehensive Cancer Center · University College, London · University Hospitals Cleveland Medical Center · University of California, San Francisco · University of Massachusetts, Worcester · University of Minnesota · University of Missouri-Columbia · University of Zurich · ALS Association · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Ain Shams University · Alana USA Foundation · Alliance for Clinical Trials in Oncology · American Academy of Neurology · Baylor College of Medicine · Bin Xu · Boehringer Ingelheim · Cairo University · Cambridge Health Alliance · Canadian Cancer Trials Group · Charite University, Berlin, Germany · Children's Hospital Medical Center, Cincinnati · Children's Oncology Group · Danish Headache Center · Dr Anne-Margot Duclot, Pain Clinic, Paris Rotschild Hospital · Dr Géraldine Brumauld de Montgazon, Pain Clinic, La Rochelle Hospital · Dr Malou Navez, Pain Clinic, Saint-Etienne Hopital · Dr Marc Sorel, Pain Clinic, Nemours Hospital · Dr Marie-Christine Crosmary/Dr Renato Colamarino, Pain Clinic, Vichy Hospital · Dr Mohamed El Ayadi, Pain Clinic, Issoire Hospital · Dr Monique Belon, Pain Clinic, Aurillac Hospital · East Kent Hospitals University NHS Foundation Trust · Eric Lenze · European Union · Evergreen Therapeutics, Inc. · Filadelfia Epilepsy Hospital · Finnish Foundation for Alcohol Studies · Finnish Institute for Health and Welfare · First Affiliated Hospital Xi'an Jiaotong University · French National Institute of Health and Medical Research · Fujian Medical University Union Hospital · Gabinete Berthier y Martínez · Gedeon Richter Plc. · German Federal Ministry of Education and Research · Guangdong Provincial People's Hospital · HaEmek Medical Center, Israel · Hannover Medical School · Harvard University · Helsinki University Central Hospital · Hoffmann-La Roche · Hyundai Pharm · all 151 on the full record

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	NAMENDA XR	—	2014-07-03	fda.gov ↗
Refused (EMA)	EU (EMA)	Nemdatine	—	2013-02-22	europa.eu ↗
Refused (EMA)	EU (EMA)	Memantine LEK	—	2013-02-21	europa.eu ↗
Refused (EMA)	EU (EMA)	Balaxur	—	2013-02-20	europa.eu ↗
Approved	US (FDA)	NAMENDA	—	2003-10-16	fda.gov ↗
Approved	EU (EMA)	Ebixa	—	2002-05-15	europa.eu ↗

Trials 158 · started per year

today

EU approved 2002

US approved 2003

19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 06 trials
Phase 0	NCT07560878	Mar 2026 → Dec 2030 expected	major depressive disorder	Mclean Hospital	Recruiting	No outcome recorded
Phase 0	NCT04966546	Jun 2022 → Dec 2025	—	University of New Mexico	Withdrawn	No outcome recorded
Phase 0	NCT04217694	Feb 2020 → Sep 2022	central nervous system cancer	Mayo Clinic	Completed	No outcome recorded
Phase 0	NCT03711825	Sep → Oct 2018	Alzheimer disease, stomach disorder	Lyndra Inc.	Completed	No outcome recorded
Phase 0	NCT03468543	Jul → Sep 2017	stomach disorder	Lyndra Inc.	Terminated	No outcome recorded
Phase 0	NCT02811627	Jun 2016 → Apr 2021	autism spectrum disorder	University of Missouri-Columbia	Completed	No outcome recorded
Phase 115 trials
Phase 1	NCT07139834	Jun 2026 → Jun 2027 expected	major depressive disorder	Jeffrey Miller	Recruiting	No outcome recorded
Phase 1	NCT07531940	Jun 2026 → May 2028 expected	Down syndrome, intellectual disability	University Hospitals Cleveland Medical Center	Not yet recruiting	No outcome recorded
Phase 1	NCT05804279	Dec 2022 → Feb 2023	—	Hyundai Pharm	Completed	No outcome recorded
Phase 1	NCT03988803	Jul → Oct 2019	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT03802162	Feb → May 2019	Alzheimer disease	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT03670095	Aug → Dec 2018	—	H. Lundbeck A/S	Completed	No outcome recorded
Phase 1	NCT03569579	Apr → May 2018	central nervous system disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01579526	Apr 2012	—	Avalo Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT01461174	Nov 2011 → Nov 2014	—	Qualissima	Completed	No outcome recorded
Phase 1	NCT01430351	Sep 2011 → Feb 2025	gliosarcoma	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 1	NCT01196065	Sep → Nov 2010	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT01188525	Aug 2010 → Jul 2011	—	French National Institute of Health and Medical Research	Completed	No outcome recorded
Phase 1	NCT01392287	May 2010 → Apr 2012	major depressive disorder	Mclean Hospital	Completed	No outcome recorded
Phase 1	NCT00136747	Jan 2004 → May 2009	nicotine dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 1	NCT02001584	? → May 2014	—	Gedeon Richter Plc.	Completed	No outcome recorded

Phase 1/24 trials
Phase 1/2	NCT05664464	Jan 2023 → Jun 2026 overdue	glioblastoma	University of Zurich	Recruiting	No outcome recorded
Phase 1/2	NCT03729128	Jul 2018 → Aug 2020	substance-related disorder	Tzu-Yun Wang	Completed	No outcome recorded
Phase 1/2	NCT00264238	Jan 2006 → Jun 2008	obsessive-compulsive disorder	Stanford University	Completed	No outcome recorded
Phase 1/2	NCT00262470	Apr 1997 → Dec 2029 expected	cardiac rhythm disease	Satish R. Raj	Active not recruiting	No outcome recorded
Phase 242 trials
Phase 2	NCT07164794	Nov 2025 → Jun 2028 expected	castration-resistant prostate carcinoma, prostate neuroendocrine neoplasm	Bin Xu	Not yet recruiting	No outcome recorded
Phase 2	NCT06727773	Aug 2025 → Jun 2029 expected	breast cancer, cognitive disorder, cognitive impairment with or without cerebellar ataxia	UNC Lineberger Comprehensive Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT06789757	Feb 2025 → Oct 2026 expected	hepatocellular carcinoma	Inova Health Care Services	Recruiting	No outcome recorded
Phase 2	NCT06679387	Oct 2024 → Oct 2025 overdue	breast cancer	Ain Shams University	Recruiting	No outcome recorded
Phase 2	NCT06594172	Sep 2024 → Dec 2025 overdue	cognitive disorder, radiation-induced disorder	Affiliated Cancer Hospital & Institute of Guangzhou Medical University	Not yet recruiting	No outcome recorded
Phase 2	NCT06501638	Aug 2024 → Mar 2025	cardiac rhythm disease	Shanghai East Hospital	Completed	No outcome recorded
Phase 2	NCT05418049	Sep 2022 → Oct 2025 overdue	fragile X syndrome	Children's Hospital Medical Center, Cincinnati	Active not recruiting	No outcome recorded
Phase 2	NCT05063851	Oct 2021 → Dec 2026 expected	Alzheimer disease	University of Virginia	Active not recruiting	No outcome recorded
Phase 2	NCT04792645	Jun 2021 → Jul 2022	neurotic excoriation, trichotillomania	University of Chicago	Completed	No outcome recorded
Phase 2	NCT04033419	Sep 2019 → Apr 2022	chemotherapy-induced neuropathy, cognitive disorder	UNC Lineberger Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT03686774	Feb 2019 → Jan 2022	neuropathy, painful	University Hospital, Clermont-Ferrand	Unknown	No outcome recorded
Phase 2	NCT03527472	Aug 2018 → Feb 2026	systemic lupus erythematosus	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 2	NCT03247218	Feb 2018 → Dec 2020	sickle cell disease	HaEmek Medical Center, Israel	Unknown	No outcome recorded
Phase 2	NCT02615847	Aug 2015 → Mar 2017	sickle cell disease	University of Zurich	Completed	No outcome recorded
Phase 2	NCT02304302	Oct 2014 → Jul 2020	Down syndrome, intellectual disability	University Hospitals Cleveland Medical Center	Completed	No outcome recorded
Phase 2	NCT02234752	Sep 2014 → Jul 2016	schizoaffective disorder, schizophrenia	Sheppard Pratt Health System	Terminated	No outcome recorded
Phase 2	NCT01703923	Nov 2012 → Sep 2013	—	Avalo Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01744444	Nov 2012 → Jul 2013	pathologic nystagmus	Hospices Civils de Lyon	Completed	No outcome recorded
Phase 2	NCT01592773	Oct 2012 → Jan 2014	autism, autism spectrum disorder 1	Forest Laboratories	Terminated	No outcome recorded
Phase 2	NCT01592747	Sep 2012 → Sep 2013	autism	Forest Laboratories	Completed	No outcome recorded
Phase 2	NCT01592786	Jun 2012 → Jul 2013	autism	Forest Laboratories	Completed	No outcome recorded
Phase 2	NCT01597349	May → Sep 2012	—	Avalo Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01602185	May 2012 → Jun 2014	neuropathy, painful	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 2	NCT01519063	Jan 2012 → Mar 2017	alcohol-related disorders	Yale University	Completed	No outcome recorded
Phase 2	NCT01585168	Dec 2011 → May 2016	—	Yale University	Completed	No outcome recorded
Phase 2	NCT01260467	Nov 2010 → Apr 2014	glioblastoma	University of Rochester	Terminated	No outcome recorded
Phase 2	NCT01261741	Nov 2010 → Aug 2011	amnestic disorder, subjective cognitive decline	Merz Pharmaceuticals GmbH	Completed	No outcome recorded
Phase 2	NCT01999894	Nov 2009 → Feb 2013	autism	Forest Laboratories	Completed	No outcome recorded
Phase 2	NCT00956085	Aug 2009 → Dec 2015	obsessive-compulsive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00872898	Apr 2009 → Aug 2012	autism	Forest Laboratories	Completed	No outcome recorded
Phase 2	NCT00880685	Mar 2009 → May 2012	kleptomania	University of Chicago	Completed	No outcome recorded
Phase 2	NCT00830375	Dec 2008 → Aug 2010	kleptomania	University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00585169	Dec 2007 → Dec 2011	pathological gambling	Yale University	Completed	No outcome recorded
Phase 2	NCT00409721	Mar 2007 → Dec 2010	amyotrophic lateral sclerosis	University of Alberta	Completed	No outcome recorded
Phase 2	NCT00630955	Jun 2006 → May 2011	alcohol-related disorders	Yale University	Completed	No outcome recorded
Phase 2	NCT00200538	Sep 2005 → ?	dementia	Nantes University Hospital	Completed	No outcome recorded
Phase 2	NCT01020331	Jun 2005 → Jul 2009	amyotrophic lateral sclerosis	Phoenix Neurological Associates, LTD	Completed	No outcome recorded
Phase 2	NCT00106405	Feb → Nov 2005	bipolar disorder	Forest Laboratories	Completed	No outcome recorded
Phase 2	NCT00097942	Aug 2004 → Sep 2005	schizophrenia	Forest Laboratories	Completed	No outcome recorded
Phase 2	NCT00134901	Mar 2003 → May 2007	cocaine dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00246415	Nov 2002 → Dec 2005	alcohol abuse, alcohol dependence	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Completed	No outcome recorded
Phase 2	NCT00000867	Dec 1996 → Jul 2001	AIDS dementia complex, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/313 trials
Phase 2/3	NCT05796752	Aug 2023 → Apr 2026 overdue	neurotic excoriation, trichotillomania	University of Chicago	Active not recruiting	No outcome recorded
Phase 2/3	NCT06007846	Jul 2023 → Jul 2026 overdue	cirrhosis of liver, hepatocellular carcinoma	Inova Health Care Services	Recruiting	No outcome recorded
Phase 2/3	NCT04737967	Feb → Aug 2021	chemotherapy-induced neuropathy	Mendel AI	Unknown	No outcome recorded
Phase 2/3	NCT04687566	Aug 2020 → Jul 2024	amphetamine abuse	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 2/3	NCT04302870	Feb 2020 → Dec 2030 expected	amyotrophic lateral sclerosis	University of Edinburgh	Recruiting	No outcome recorded
Phase 2/3	NCT04035798	Aug 2019 → Jul 2021	bipolar II disorder	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 2/3	NCT03342443	Dec 2017 → Oct 2024	cognitive impairment with or without cerebellar ataxia	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Unknown	No outcome recorded
Phase 2/3	NCT01052662	Oct 2009 → Jun 2013	opiate dependence	University of Massachusetts, Worcester	Completed	No outcome recorded
Phase 2/3	NCT01188148	Aug 2009 → Oct 2012	bipolar disorder	National Cheng-Kung University Hospital	Completed	No outcome recorded
Phase 2/3	NCT00476242	Jun 2008 → Aug 2011	heroin dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2/3	NCT01876823	Apr 2006 → Mar 2010	Alzheimer disease, cognitive impairment with or without cerebellar ataxia, major depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2/3	NCT00353665	Jul 2005 → Jun 2008	amyotrophic lateral sclerosis	University of Lisbon	Completed	No outcome recorded
Phase 2/3	NCT00300716	Apr 2004 → Jan 2009	cognitive disorder, multiple sclerosis	Oregon Health and Science University	Completed	No outcome recorded

Phase 327 trials
Phase 3	NCT06275035	Feb 2024 → Jan 2026 overdue	cognitive disorder	Tata Memorial Centre	Recruiting	No outcome recorded
Phase 3	NCT04939597	May 2022 → Jun 2026 overdue	central nervous system cancer	Children's Oncology Group	Active not recruiting	No outcome recorded
Phase 3	NCT04588246	Aug 2021 → Aug 2024	digestive system cancer, female breast carcinoma, metastatic malignant neoplasm in the brain, metastatic melanoma +3	NRG Oncology	Terminated	No outcome recorded
Phase 3	NCT03858270	Apr 2019 → Apr 2022	Parkinson disease	Wayne State University	Unknown	No outcome recorded
Phase 3	NCT03550391	Nov 2018 → Jun 2027 expected	metastatic malignant neoplasm in the brain	Canadian Cancer Trials Group	Recruiting	No outcome recorded
Phase 3	NCT02950233	May 2017 → Dec 2018	neuropathy, painful	Population Health Research Institute	Terminated	No outcome recorded
Phase 3	NCT01972074	Feb 2015 → May 2018	autism spectrum disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT02374567	Jan 2015 → Jun 2017	anxiety disorder, dementia, depressive disorder, schizophrenia +1	Hannover Medical School	Terminated	No outcome recorded
Phase 3	NCT03043001	Jan 2014 → Dec 2016	—	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 3	NCT03039842	Jan 2013 → Dec 2016	bipolar II disorder	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 3	NCT01536314	Feb 2012 → Nov 2013	neuropathy, painful	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 3	NCT01189214	Mar 2009 → Feb 2011	substance abuse	National Cheng-Kung University Hospital	Completed	No outcome recorded
Phase 3	NCT00804271	Dec 2008 → Nov 2009	Alzheimer disease	Merz Pharmaceuticals GmbH	Completed	No outcome recorded
Phase 3	NCT00566852	Mar 2008 → Apr 2011	cognitive disorder, metastatic malignant neoplasm, poisoning	Radiation Therapy Oncology Group	Completed	No outcome recorded
Phase 3	NCT00624026	Nov 2007 → Dec 2008	Alzheimer disease	Merz Pharmaceuticals GmbH	Completed	No outcome recorded
Phase 3	NCT00594737	Oct 2007 → Jun 2012	frontotemporal dementia	Tiffany Chow, MD	Completed	No outcome recorded
Phase 3	NCT00235716	Aug 2007 → Sep 2012	Alzheimer disease	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 3	NCT00411398	Dec 2006 → May 2010	generalized anxiety disorder, social phobia	State University of New York - Upstate Medical University	Completed	No outcome recorded
Phase 3	NCT00315666	May 2006 → Jun 2007	—	Danish Headache Center	Completed	No outcome recorded
Phase 3	NCT01074619	Sep 2005 → Mar 2011	multiple sclerosis	University Hospital, Caen	Completed	No outcome recorded
Phase 3	NCT00255086	May 2005 → Jun 2009	Alzheimer disease	Stanford University	Completed	No outcome recorded
Phase 3	NCT00097916	Sep 2004 → Apr 2006	Alzheimer disease	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT00857233	Jun 2004 → Jul 2010	Alzheimer disease	H. Lundbeck A/S	Terminated	No outcome recorded
Phase 3	NCT00857649	Dec 2003 → Apr 2010	Alzheimer disease	H. Lundbeck A/S	Terminated	No outcome recorded
Phase 3	NCT00040261	Jun 2002 → Mar 2005	depressive disorder	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 3	NCT00168350	Mar 2000 → Sep 2006	open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 3	NCT00141882	Mar 1999 → Jan 2006	open-angle glaucoma	Allergan	Completed	No outcome recorded

Phase 439 trials
Phase 4	NCT05430867	Jul 2022 → Jul 2024	Alzheimer disease	First Affiliated Hospital Xi'an Jiaotong University	Unknown	No outcome recorded
Phase 4	NCT04117178	Feb 2020 → Feb 2023	Alzheimer disease, Lewy body dementia, Parkinson disease	Zealand University Hospital	Completed	No outcome recorded
Phase 4	NCT03703856	Jan 2019 → Jan 2025	Alzheimer disease	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT03168997	Jul 2017 → Sep 2018	Alzheimer disease	Wei Cuibai	Unknown	No outcome recorded
Phase 4	NCT02553928	Oct 2015 → Jul 2016	Alzheimer disease	H. Lundbeck A/S	Completed	No outcome recorded
Phase 4	NCT02466191	Jun 2015 → Jan 2016	pathologic nystagmus	Hospices Civils de Lyon	Completed	No outcome recorded
Phase 4	NCT01656187	Jan 2012 → Jan 2017	amnestic disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT02467556	Mar 2011 → May 2014	complex regional pain syndrome type 1	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT01333865	Jan 2010 → Jul 2014	autism spectrum disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00933608	Jul 2009 → Sep 2011	Alzheimer disease	NYU Langone Health	Completed	No outcome recorded
Phase 4	NCT00649220	Jul 2008 → May 2009	Alzheimer disease	Merz Pharmaceuticals GmbH	Terminated	No outcome recorded
Phase 4	NCT01112683	Jul 2008 → Jul 2011	Down syndrome	University of Colorado, Denver	Completed	No outcome recorded
Phase 4	NCT00800709	Jul 2008 → Oct 2010	Alzheimer disease	Shanghai Mental Health Center	Completed	No outcome recorded
Phase 4	NCT00545974	Oct 2007 → Dec 2012	semantic dementia	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT00371059	Sep 2007 → Jun 2009	dementia	East Kent Hospitals University NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT00551161	Aug 2007 → Dec 2011	Alzheimer disease	Northwell Health	Completed	No outcome recorded
Phase 4	NCT00462228	Apr 2007 → Dec 2010	traumatic brain injury	University of Missouri-Columbia	Terminated	No outcome recorded
Phase 4	NCT00586573	Mar 2007 → Oct 2009	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00439699	Feb 2007 → Dec 2008	essential tremor	VA Greater Los Angeles Healthcare System	Completed	No outcome recorded
Phase 4	NCT00855686	Jan 2007 → Dec 2008	Lewy body dementia, Parkinson disease	H. Lundbeck A/S	Completed	No outcome recorded
Phase 4	NCT00401167	Nov 2006 → Jan 2010	Alzheimer disease	Sunnybrook Health Sciences Centre	Completed	No outcome recorded
Phase 4	NCT00638027	Jul 2006 → Feb 2009	multiple sclerosis	University of Rochester	Completed	No outcome recorded
Phase 4	NCT00344682	Jun 2006 → Dec 2011	depressive disorder	University of Massachusetts, Worcester	Completed	No outcome recorded
Phase 4	NCT00330655	May 2006 → Jul 2007	binge eating disorder	Mclean Hospital	Completed	No outcome recorded
Phase 4	NCT00646204	Apr 2006 → Feb 2009	Parkinson disease	Baylor College of Medicine	Completed	No outcome recorded
Phase 4	NCT00303433	Mar → Sep 2006	delirium	University of Rochester	Terminated	No outcome recorded
Phase 4	NCT00280774	Mar 2006 → Feb 2007	—	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT00305903	Mar 2006 → Aug 2007	Alzheimer disease	Novartis	Completed	No outcome recorded
Phase 4	NCT00368862	Dec 2005 → Jun 2006	alcohol dependence, depressive disorder	Finnish Institute for Health and Welfare	Completed	No outcome recorded
Phase 4	NCT00586066	Nov 2005 → Dec 2009	bipolar disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00862940	Sep 2005 → Feb 2009	Alzheimer disease	H. Lundbeck A/S	Completed	No outcome recorded
Phase 4	NCT00183729	Aug 2005 → Jun 2009	depressive disorder	Eric Lenze	Completed	No outcome recorded
Phase 4	NCT02258828	Jul 2005 → Mar 2007	post-traumatic stress disorder	Sriram Ramaswamy	Completed	No outcome recorded
Phase 4	NCT00334906	Jul 2005 → Nov 2007	Alzheimer disease	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT00196703	Mar → Sep 2005	aphasia, stroke disorder	Gabinete Berthier y Martínez	Unknown	No outcome recorded
Phase 4	NCT00652457	Nov 2004 → Oct 2009	Huntington disease	Jody Corey-Bloom, MD, PhD	Completed	No outcome recorded
Phase 4	NCT01921972	Nov 2004 → Nov 2008	Alzheimer disease	Charite University, Berlin, Germany	Completed	No outcome recorded
Phase 4	NCT00187525	May 2004 → Oct 2005	frontotemporal dementia	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT00234637	Nov 2003 → Jun 2005	Alzheimer disease	Novartis	Completed	No outcome recorded

Phase not applicable12 trials
—	NCT02240589	Dec 2014 → Apr 2016	traumatic brain injury	Indiana University	Completed	No outcome recorded
—	NCT02233556	Feb 2014 → Dec 2016	schizophrenia	National Taiwan University Hospital	Unknown	No outcome recorded
—	NCT01038128	Dec 2009 → May 2011	body dysmorphic disorder, bulimia nervosa	Mclean Hospital	Completed	No outcome recorded
—	NCT02136823	Jun 2009 → May 2015	spinal cord injury	Shirley Ryan AbilityLab	Unknown	No outcome recorded
—	NCT01054599	Jan 2009 → May 2014	epilepsy	American Academy of Neurology	Completed	No outcome recorded
—	NCT00703430	Mar 2008 → Dec 2013	Alzheimer disease	Peking University	Unknown	No outcome recorded
—	NCT00584948	Sep 2007 → Sep 2012	fragile X syndrome, fragile X-associated tremor/ataxia syndrome	University of California, Davis	Completed	No outcome recorded
—	NCT00240760	Oct 2005 → ?	Down syndrome, dementia, learning disability	King's College London	Unknown	No outcome recorded
—	NCT00375778	Apr 2005 → Sep 2006	Parkinson disease	University of Aarhus	Completed	No outcome recorded
—	NCT00242632	Jun 2004 → Dec 2009	dementia	Stanford University	Completed	No outcome recorded
—	NCT00186498	Feb 2004 → Feb 2006	major depressive disorder	Stanford University	Completed	No outcome recorded
—	NCT00241995	—	—	St. Petersburg State Pavlov Medical University	Completed	No outcome recorded

Also used as a comparator or background therapy in 82 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT02144584 Comparator	Jan 2014 → Dec 2026 expected	ischemic stroke	University of Utah	Active not recruiting	No outcome recorded
Phase 16 trials
Phase 1	NCT07094438 Comparator	Jan 2025 → Jun 2026 overdue	Alzheimer disease	Chinese PLA General Hospital	Recruiting	No outcome recorded
Phase 1	NCT04789915 Comparator	May 2021 → Jul 2025 overdue	psychotic disorder	Bjorn H. Ebdrup	Recruiting	No outcome recorded
Phase 1	NCT04417543 Comparator	Oct 2018 → Oct 2019	epilepsy	Assiut University	Completed	No outcome recorded
Phase 1	NCT03316898 Background	Sep → Nov 2018	Alzheimer disease	Allergan	Withdrawn	No outcome recorded
Phase 1	NCT02288000 Comparator	Sep 2016 → Dec 2020	Alzheimer disease	University Hospital, Lille	Terminated	No outcome recorded
Phase 1	NCT00136786 Comparator	Dec 2006 → May 2009	nicotine dependence	New York State Psychiatric Institute	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT05834231 Comparator	Aug 2023 → Mar 2024	cancer	Mansoura University	Unknown	No outcome recorded
Phase 1/2	NCT01555697 Comparator	Jul 2014 → Jun 2019	schizophrenia	University of California, San Diego	Completed	No outcome recorded
Phase 220 trials
Phase 2	NCT07248228 Background	Jul 2026 → May 2027 expected	metastatic malignant neoplasm in the brain	Case Comprehensive Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT07470606 Background	Mar 2026 → Mar 2030 expected	brain neoplasm	The University of Texas Health Science Center at San Antonio	Not yet recruiting	No outcome recorded
Phase 2	NCT06041789 Comparator	Feb 2025 → Nov 2026 expected	osteoporosis	Duke University	Recruiting	No outcome recorded
Phase 2	NCT05538507 Comparator	Jun 2022 → Jun 2024	Alzheimer disease, cognitive impairment with or without cerebellar ataxia	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 2	NCT05013892 Background	Feb 2022 → Dec 2027 expected	metastatic malignant neoplasm in the brain	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 2	NCT05045950 Background	Nov 2021 → May 2028 expected	metastatic malignant neoplasm in the brain	Medical College of Wisconsin	Recruiting	No outcome recorded
Phase 2	NCT04801342 Background	Apr 2021 → Jan 2024	metastatic malignant neoplasm in the brain	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 2	NCT04539951 Comparator	Sep 2020 → Jun 2027 expected	obsessive-compulsive disorder	Shanghai Mental Health Center	Recruiting	No outcome recorded
Phase 2	NCT02118727 Comparator	Nov 2018 → Jul 2021	amyotrophic lateral sclerosis, frontotemporal dementia	University of Kansas Medical Center	Completed	No outcome recorded
Phase 2	NCT03194906 Comparator	Nov 2017 → Jun 2023	brain glioma, craniopharyngioma, ependymoma, germ cell tumor	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 2	NCT02580305 Comparator	Sep 2015 → Nov 2019	Alzheimer disease	Suven Life Sciences Limited	Completed	No outcome recorded
Phase 2	NCT02097706 Comparator	Jan 2015 → Dec 2025 overdue	borderline personality disorder	The Alfred	Recruiting	No outcome recorded
Phase 2	NCT02630888 Comparator	Aug 2014 → Apr 2020	bipolar I disorder	University of Sao Paulo	Unknown	No outcome recorded
Phase 2	NCT01677754 Background	Oct 2012 → Jun 2015	Alzheimer disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT01535040 Comparator	Aug 2012 → Feb 2014	breast cancer, colorectal cancer, lung cancer, nicotine dependence +1	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 2	NCT01372449 Comparator	Dec 2011 → Oct 2015	autism spectrum disorder	Evdokia Anagnostou	Completed	No outcome recorded
Phase 2	NCT01458470 Comparator	Sep 2011 → Aug 2012	Huntington disease	University of British Columbia	Completed	No outcome recorded
Phase 2	NCT00638833 Comparator	Sep 2007 → Mar 2008	multiple sclerosis	Clinica Universidad de Navarra, Universidad de Navarra	Terminated	No outcome recorded
Phase 2	NCT00630500 Comparator	Feb 2006 → Feb 2009	Lewy body dementia, Parkinson disease	Helse Stavanger HF	Completed	No outcome recorded
Phase 2	NCT00125515 Comparator	Jun 2005 → Aug 2008	opiate dependence	New York State Psychiatric Institute	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT07504198 Comparator	Mar 2026 → Apr 2027 expected	peripheral neuropathy	Tanta University	Not yet recruiting	No outcome recorded
Phase 2/3	NCT06914310 Comparator	Mar → Aug 2025 overdue	traumatic brain injury	Mansoura University	Not yet recruiting	No outcome recorded
Phase 2/3	NCT04857983 Comparator	Jul 2021 → Mar 2025	schizoaffective disorder, schizophrenia	University of California, San Diego	Completed	No outcome recorded
Phase 317 trials
Phase 3	NCT05564169 Background	Jun 2026 → Dec 2028 expected	Alzheimer disease	AB Science	Not yet recruiting	No outcome recorded
Phase 3	NCT07251023 Comparator	Nov 2025 → May 2027 expected	Alzheimer disease	Bigespas LTD	Recruiting	No outcome recorded
Phase 3	NCT06337994 Comparator	Jan → Jun 2024	—	Assiut University	Completed	No outcome recorded
Phase 3	NCT05015595 Comparator	Sep 2021 → Oct 2022	obsessive-compulsive disorder	University of Roma La Sapienza	Unknown	No outcome recorded
Phase 3	NCT04804644 Comparator	Jun 2021 → Jun 2026 overdue	metastatic malignant neoplasm in the brain, small cell lung carcinoma	NRG Oncology	Recruiting	No outcome recorded
Phase 3	NCT04698525 Comparator	Feb 2019 → Jan 2020	migraine disorder	Autonomous University of San Luis Potosí	Completed	No outcome recorded
Phase 3	NCT03553875 Comparator	Nov 2018 → Nov 2025	autism, non-verbal learning disability	Massachusetts General Hospital	Terminated	No outcome recorded
Phase 3	NCT02535611 Comparator	Oct 2015 → Oct 2016	ischemic stroke	Mazandaran University of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT02360215 Background	Jul 2015 → Apr 2018	cognitive impairment with or without cerebellar ataxia, metastatic malignant neoplasm in the brain	NRG Oncology	Completed	No outcome recorded
Phase 3	NCT02001103 Comparator	Jan 2014 → Jul 2016	schizophrenia	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 3	NCT01653457 Comparator	Sep → Oct 2012	fibromyalgia	Aragon Institute of Health Sciences	Unknown	No outcome recorded
Phase 3	NCT01872598 Background	Jan 2012 → Dec 2020	Alzheimer disease	AB Science	Completed	No outcome recorded
Phase 3	NCT01409694 Comparator	Sep 2011 → Jan 2016	Alzheimer disease	University Hospital, Angers	Completed	No outcome recorded
Phase 3	NCT00148590 Comparator	Nov 2005 → Jun 2008	schizophrenia	M. Schaefer, MD	Terminated	No outcome recorded
Phase 3	NCT00322153 Comparator	Jun 2005 → Oct 2007	Alzheimer disease	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT00674219 Comparator	May 2005 → Jan 2008	generalized anxiety disorder, obsessive-compulsive disorder	University of California, Los Angeles	Completed	No outcome recorded
Phase 3	NCT00148616 Comparator	Apr 2004 → Jun 2008	schizophrenia	M. Schaefer, MD	Terminated	No outcome recorded

Phase 421 trials
Phase 4	NCT07417670 Comparator	Oct 2024 → Aug 2025	Alzheimer disease	Carnot Laboratories	Completed	No outcome recorded
Phase 4	NCT03954613 Background	Oct 2020 → Mar 2023	Alzheimer disease	Neutec Ar-Ge San ve Tic A.Ş	Unknown	No outcome recorded
Phase 4	NCT03779672 Comparator	Feb 2019 → Nov 2021	childhood-onset epilepsy syndrome with developmental and/or epileptic encephalopathy	Kenneth Myers, MD	Completed	No outcome recorded
Phase 4	NCT03860597 Comparator	Apr 2018 → Mar 2021	schizoaffective disorder, schizophrenia	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT02670161 Comparator	May 2016 → Dec 2026 expected	Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6	Endeavor Health	Enrolling by invitation	No outcome recorded
Phase 4	NCT01902004 Comparator	Oct 2013 → Jan 2019	cognitive disorder, depressive disorder	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT01849042 Comparator	Jan 2013 → Aug 2014	Alzheimer disease	Konkuk University Medical Center	Unknown	No outcome recorded
Phase 4	NCT01041313 Comparator	Jan 2010 → Jun 2011	neuropathy, painful	University of Washington	Unknown	No outcome recorded
Phase 4	NCT01032759 Comparator	Dec 2009 → Jan 2015	—	Duke University	Terminated	No outcome recorded
Phase 4	NCT01108029 Comparator	Oct 2009 → Sep 2010	Parkinson disease, movement disorder	University Hospital, Lille	Completed	No outcome recorded
Phase 4	NCT01025466 Comparator	Dec 2008 → Nov 2009	Alzheimer disease	Inha University Hospital	Completed	No outcome recorded
Phase 4	NCT00866060 Comparator	Feb 2008 → Feb 2012	Alzheimer disease	King's College London	Unknown	No outcome recorded
Phase 4	NCT00505167 Comparator	Jul 2007 → Jul 2008	Alzheimer disease	Hospital Miguel Servet	Completed	No outcome recorded
Phase 4	NCT00476008 Comparator	Jul 2007 → Oct 2012	Alzheimer disease	Florida Atlantic University	Completed	No outcome recorded
Phase 4	NCT00469456 Comparator	Apr 2007 → Nov 2008	Alzheimer disease	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT00120874 Background	Aug 2006 → Nov 2011	Alzheimer disease	NYU Langone Health	Completed	No outcome recorded
Phase 4	NCT00757978 Comparator	Jan 2006 → Jan 2008	schizophrenia	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
Phase 4	NCT00283309 Comparator	Nov 2005 → Apr 2007	—	University of Texas Southwestern Medical Center	Terminated	No outcome recorded
Phase 4	NCT00305578 Comparator	Aug 2005 → Dec 2010	bipolar depression	Indiana University	Completed	No outcome recorded
Phase 4	NCT00640198 Comparator	Mar 2005 → Nov 2007	aphasia, stroke disorder	Gabinete Berthier y Martínez	Completed	No outcome recorded
Phase 4	NCT00768261 Comparator	Nov 2004 → Oct 2009	dementia	Washington University School of Medicine	Completed	No outcome recorded

Phase not applicable12 trials
—	NCT07351773 Background	Jan → Jun 2025	Alzheimer disease	Taizhou Second People's Hospital	Completed	No outcome recorded
—	NCT05531383 Comparator	Nov 2021 → Nov 2023	traumatic brain injury	Minia University	Unknown	No outcome recorded
—	NCT05102045 Background	Sep 2016 → May 2017	Alzheimer disease	Istanbul Medipol University Hospital	Completed	No outcome recorded
—	NCT01844427 Comparator	Jul 2013 → Mar 2015	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Withdrawn	No outcome recorded
—	NCT01533493 Comparator	May 2012 → Jul 2013	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT00986115 Comparator	Jul 2010 → Jan 2012	epilepsy	University of California, Davis	Withdrawn	No outcome recorded
—	NCT01078844 Comparator	Feb → Jul 2010	autism spectrum disorder	Johns Hopkins University	Terminated	No outcome recorded
—	NCT00988663 Comparator	Nov 2009	major depressive disorder	Jerrry L Lewis	Withdrawn	No outcome recorded
—	NCT00980408 Comparator	Jun 2008 → Aug 2011	—	University Hospital, Bonn	Completed	No outcome recorded
—	NCT00294554 Comparator	Apr 2006 → Sep 2008	Parkinson disease, dementia	Johns Hopkins University	Completed	No outcome recorded
—	NCT00181298 Comparator	Mar 2006 → May 2007	systemic lupus erythematosus	Johns Hopkins University	Completed	No outcome recorded
—	NCT00928954 Comparator	Feb 2005 → May 2009	pathologic nystagmus	Case Western Reserve University	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2019-10-28	AbbVie	Forest Resolves Antitrust Class Action Litigation with Direct Purchasers of Namenda abbvie.com ↗

Evidence & citations 26 cited values

Every value below carries the sentence it was read from. 244 sources stand behind the page.

Field	Value	Cited text
Known as	Memantine	“Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19,...” PMID 25465228 ↗ Dec 2014 227 “Group 2: 15 patients receive (10 mg) of Namenda (memantine) Day --8,--7,--6,--5,--4,--3,--2, then 20 mg per day on Day --1, day 0 (surgery), Post-op day 1,2,3 then 10 mg per...” NCT00303433 ↗ “NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10...” NCT02950233 ↗ “This study compared the pharmacokinetic (PK) characteristics and safety profiles of an FDC formulation (donepezil/memantine [10/20 mg]) and single components (SCs) of donepezil...” PMID 40444644 ↗ May 2025 “The study is aimed to evaluate the efficacy of antiglutamate anticonvulsants (topiramate, lamotrigine, and memantine) in the treatment of alcohol withdrawal syndrome” NCT00241995 ↗ “Patients in the medication group received only the currently recognized pharmacological treatments for AD, including Memantine Hydrochloride and Donepezil.” NCT07094438 ↗ “Memantine-HCl is a voltage-dependent N-methyl-D-aspartate (NMDA) receptor 'channel blocker' that selectively blocks pathological glutamate overactivity.” PMID 29549516 ↗ Feb 2018 “Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)” NCT03711825 ↗ “stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.” NCT01872598 ↗ “Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine” NCT05564169 ↗ “Receiving Donepezil, Memantine or Donepezil/Memantine Combination Therapy” NCT03954613 ↗ “Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily” NCT06007846 ↗ “mild cognitive impairment (donepezil, rivastigmine, memantine)” NCT02670161 ↗ “Naltrexone 50mg memantine 20mg” NCT01519063 ↗ NCT02553928 ↗ NCT00956085 ↗ NCT03686774 ↗ NCT06041789 ↗ NCT01458470 ↗ NCT00097942 ↗ NCT00551161 ↗ NCT00830375 ↗ NCT07251023 ↗ NCT01054599 ↗ NCT00594737 ↗ NCT00630955 ↗ NCT04302870 ↗ NCT07417670 ↗ NCT02258828 ↗ NCT00141882 ↗ NCT00200538 ↗ NCT00106405 ↗ NCT03553875 ↗ NCT01189214 ↗ NCT05430867 ↗ NCT07248228 ↗ NCT00344682 ↗ NCT00872898 ↗ NCT00305903 ↗ NCT00630500 ↗ NCT00136747 ↗ NCT00409721 ↗ NCT01032759 ↗ NCT04035798 ↗ NCT00305578 ↗ NCT05834231 ↗ NCT00586066 ↗ NCT00187525 ↗ NCT00183729 ↗ NCT04117178 ↗ NCT01536314 ↗ NCT00866060 ↗ NCT01020331 ↗ NCT04966546 ↗ NCT00585169 ↗ NCT02811627 ↗ NCT03550391 ↗ NCT00624026 ↗ NCT01333865 ↗ NCT03342443 ↗ NCT00505167 ↗ NCT00880685 ↗ NCT01876823 ↗ NCT00334906 ↗ NCT01188148 ↗ NCT00584948 ↗ NCT04792645 ↗ NCT03039842 ↗ NCT01656187 ↗ NCT03802162 ↗ NCT01052662 ↗ NCT07164794 ↗ NCT01112683 ↗ NCT01038128 ↗ NCT01430351 ↗ NCT04033419 ↗ NCT05102045 ↗ NCT06679387 ↗ NCT02630888 ↗ NCT05664464 ↗ NCT00638027 ↗ NCT02466191 ↗ NCT00768261 ↗ NCT03527472 ↗ NCT02136823 ↗ NCT05045950 ↗ NCT04737967 ↗ NCT05015595 ↗ NCT02240589 ↗ NCT00134901 ↗ NCT00439699 ↗ NCT00294554 ↗ NCT00040261 ↗ NCT00411398 ↗ NCT06914310 ↗ NCT00674219 ↗ NCT01041313 ↗ NCT04217694 ↗ NCT07470606 ↗ NCT01108029 ↗ NCT02360215 ↗ NCT05531383 ↗ NCT00800709 ↗ NCT00235716 ↗ NCT00703430 ↗ NCT04539951 ↗ NCT01025466 ↗ NCT07531940 ↗ NCT01677754 ↗ NCT07139834 ↗ NCT02001584 ↗ NCT00240760 ↗ NCT00638833 ↗ NCT00652457 ↗ NCT00322153 ↗ NCT01260467 ↗ NCT00928954 ↗ NCT00264238 ↗ NCT02304302 ↗ NCT03779672 ↗ NCT00330655 ↗ NCT00186498 ↗ NCT01902004 ↗ NCT02467556 ↗ NCT00757978 ↗ NCT03988803 ↗ NCT04687566 ↗ NCT00855686 ↗ NCT02001103 ↗ NCT03569579 ↗ NCT01653457 ↗ NCT02535611 ↗ NCT07560878 ↗ NCT04588246 ↗ NCT02288000 ↗ NCT00980408 ↗ NCT00462228 ↗ NCT03703856 ↗ NCT00315666 ↗ NCT05538507 ↗ NCT00168350 ↗ NCT03168997 ↗ NCT01602185 ↗ NCT01844427 ↗ NCT00300716 ↗ NCT02234752 ↗ NCT03670095 ↗ NCT02233556 ↗ NCT00469456 ↗ NCT00476008 ↗ NCT01078844 ↗ NCT01555697 ↗ NCT00375778 ↗ NCT06275035 ↗ NCT03858270 ↗ NCT03316898 ↗ NCT00862940 ↗ NCT01999894 ↗ NCT00401167 ↗ NCT00857233 ↗ NCT00545974 ↗ NCT00368862 ↗ NCT00476242 ↗ NCT00280774 ↗ NCT03194906 ↗ NCT00353665 ↗ NCT00804271 ↗ NCT00246415 ↗ NCT00262470 ↗ NCT03729128 ↗ NCT01972074 ↗ NCT02580305 ↗ NCT05013892 ↗ NCT01535040 ↗ NCT00148590 ↗ NCT00148616 ↗ NCT04857983 ↗ NCT05796752 ↗ NCT00857649 ↗ NCT01392287 ↗ NCT01196065 ↗ NCT04789915 ↗ NCT01372449 ↗ NCT03860597 ↗ NCT01461174 ↗ NCT00649220 ↗ NCT00136786 ↗ NCT00371059 ↗ NCT06594172 ↗ NCT00120874 ↗ NCT04417543 ↗ NCT00097916 ↗ NCT00988663 ↗ NCT03247218 ↗ NCT00000867 ↗ NCT03468543 ↗ NCT00640198 ↗ NCT00646204 ↗ NCT06501638 ↗ NCT05418049 ↗ NCT05063851 ↗ NCT01592747 ↗ NCT02374567 ↗ NCT01744444 ↗ NCT00125515 ↗ NCT01409694 ↗ NCT04698525 ↗ NCT01592773 ↗ NCT07504198 ↗ NCT02144584 ↗ NCT01585168 ↗ NCT06337994 ↗ NCT00283309 ↗ NCT01592786 ↗ NCT00566852 ↗ NCT00986115 ↗ NCT02118727 ↗ NCT03043001 ↗ NCT06727773 ↗ NCT00255086 ↗ NCT00196703 ↗ NCT01921972 ↗ NCT00234637 ↗ NCT00181298 ↗ NCT04939597 ↗ NCT00933608 ↗ NCT01261741 ↗ NCT01074619 ↗
Known as	Akatinol memantine	“Memantine (Akatinol memantine), an agent that is approved in Germany for dementia syndrome, Parkinson's disease has significant antiglutamatergic and neuroprotective...” NCT00040261 ↗
Known as	Axura	“Memantine (Axura®, Merz, active ingredient: Memantine, dose: 20 mg)” NCT00980408 ↗
Known as	Chlorhydrate de mémantine (Ebixa)	“Chlorhydrate de mémantine (Ebixa®)” NCT01409694 ↗
Known as	D324	“D324 (Memantine HCl 10mg)” NCT03802162 ↗
Known as	EBIXA	“Depolan (morphine), Ebixa (memantine)” NCT02467556 ↗ 3 “Ebixa (memantine hydrochloride)” NCT00368862 ↗ “Memantine EBIXA®” NCT01536314 ↗ NCT01849042 ↗
Known as	Ebixa (Memantine)	“Ebixa (Memantine)” NCT00505167 ↗
Known as	Eutebrol	“Eutebrol® (conventional Memantine Tablets) 10 mg.” NCT07417670 ↗
Known as	FP01	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01703923 ↗ 2 NCT01579526 ↗ NCT01597349 ↗
Known as	MEM	“Deficits in early auditory information processing mediate both neurocognitive and functional impairment and appear to be normalized by acute pharmacologic challenge with the...” PMID 32340927 ↗ Feb 2020 1 “Memantine (MEM) is an FDA-approved treatment for Alzheimer's Disease (AD)” NCT03703856 ↗
Known as	Memantine ER	“Memantine ER results in early, maintained improvement in patients with moderate to severe Alzheimer's disease concurrently taking ChEIs, compared with cholinesterase treatment alone.” PMID 29771687 ↗ Jul 2018
Known as	Memantine extended release (ER)	“Memantine extended release (ER) significantly outperformed placebo on co-primary endpoints of Clinician's Interview-based Impression of Change Plus Caregiver Input (CIBIC-Plus)...” PMID 29771687 ↗ Jul 2018
Known as	Memantine HC1	“This is a 12-week clinical trial evaluating the efficacy and safety of memantine hydrochloride (Memantine HC1, brand name Namenda) in the treatment of executive function...” NCT01844427 ↗
Known as	Memantine HCl	“Memantine-HCl is a voltage-dependent N-methyl-D-aspartate (NMDA) receptor 'channel blocker' that selectively blocks pathological glutamate overactivity.” PMID 29549516 ↗ Feb 2018 2 “Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.” NCT01844427 ↗ “CKD-355A (D797/Memantine HCl 20mg)” NCT03802162 ↗
Known as	memantine hydrochloride	“The N-methyl-D-aspartate (NMDA) receptor uncompetitive antagonist, memantine hydrochloride (memantine), has been shown to improve learning/memory and rescue one form of...” PMID 22806212 ↗ Jul 2012 14 “This is a 12-week clinical trial evaluating the efficacy and safety of memantine hydrochloride (Memantine HC1, brand name Namenda) in the treatment of executive function...” NCT01844427 ↗ “Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated.” NCT01392287 ↗ “Memantine Teva® film-coated tablets (Memantine hydrochloride) is produced by Teva Pharma AG and will be provided as 5 mg, 10 mg, and 20 mg tablets packed in blister.” NCT03247218 ↗ “Randomized Double-blind Placebo-controlled Trial of Memantine Hydrochloride for the Treatment of Childhood-onset Epileptic Encephalopathies” NCT03779672 ↗ “oral memantine hydrochloride (memantine) administered for a period of 6 months” NCT04939597 ↗ “Memantine Hydrochloride (the study medication)” NCT02304302 ↗ “Ebixa (memantine hydrochloride)” NCT00368862 ↗ “Drug: Memantine Hydrochloride” NCT04966546 ↗ NCT04804644 ↗ NCT00586573 ↗ NCT07351773 ↗ NCT04801342 ↗ NCT01533493 ↗ NCT06789757 ↗
Known as	Memantine Hydrochloride (HCl)	“Drug: Memantine Hydrochloride (HCl)” NCT01592773 ↗
Known as	Memantine or Namenda	“Memantine or Namenda” NCT00305578 ↗
Known as	Memantine Teva	“Memantine Teva® film-coated tablets (Memantine hydrochloride) is produced by Teva Pharma AG and will be provided as 5 mg, 10 mg, and 20 mg tablets packed in blister.” NCT03247218 ↗
Known as	Memantine XR	“Drug: Memantine XR” NCT02144584 ↗
Known as	memantinehydrochlorid	“Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.” NCT02615847 ↗
Known as	Memantinhydrochlorid	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02615847 ↗
Known as	Namenda	“This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder,...” NCT03553875 ↗ 5 “This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD).” NCT00187525 ↗ “Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder” NCT00411398 ↗ “memantine (Namenda), in doses up to 20 mg/day” NCT00264238 ↗ “Memantine (Namenda®)” NCT00768261 ↗ NCT00242632 ↗
Known as	Namenda XR	“Memantine is available commercially as Namenda, Namenda XR and in the liquid form (for subjects who do not wish to take pills).” NCT02811627 ↗
Known as	Sinolvir	“Sinolvir® (Orodispersible Memantine) 10 mg.” NCT07417670 ↗
Action	Inhibit	“memantine, an uncompetitive antagonist of the N-methyl-D-aspartate receptor as treatment of HIV-associated cognitive impairment” PMID 17721095 ↗ Sep 2007
Route	Oral	“oral memantine” NCT00246415 ↗